These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 15196057

  • 1. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.
    Brinkmann V, Cyster JG, Hla T.
    Am J Transplant; 2004 Jul; 4(7):1019-25. PubMed ID: 15196057
    [Abstract] [Full Text] [Related]

  • 2. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
    Butler J, Lana D, Round O, LaMontagne K.
    Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
    [Abstract] [Full Text] [Related]

  • 3. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
    Kihara A, Igarashi Y.
    Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
    [Abstract] [Full Text] [Related]

  • 4. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K.
    Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
    [Abstract] [Full Text] [Related]

  • 5. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
    Chiba K, Matsuyuki H, Maeda Y, Sugahara K.
    Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
    [Abstract] [Full Text] [Related]

  • 6. Endothelial barrier protection by FTY720 under hyperglycemic condition: involvement of focal adhesion kinase, small GTPases, and adherens junction proteins.
    Sarai K, Shikata K, Shikata Y, Omori K, Watanabe N, Sasaki M, Nishishita S, Wada J, Goda N, Kataoka N, Makino H.
    Am J Physiol Cell Physiol; 2009 Oct; 297(4):C945-54. PubMed ID: 19657053
    [Abstract] [Full Text] [Related]

  • 7. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [Abstract] [Full Text] [Related]

  • 8. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
    Baumruker T, Billich A, Brinkmann V.
    Expert Opin Investig Drugs; 2007 Mar 22; 16(3):283-9. PubMed ID: 17302523
    [Abstract] [Full Text] [Related]

  • 9. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.
    Cyster JG, Schwab SR.
    Annu Rev Immunol; 2012 Mar 22; 30():69-94. PubMed ID: 22149932
    [Abstract] [Full Text] [Related]

  • 10. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.
    Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG.
    Nature; 2004 Jan 22; 427(6972):355-60. PubMed ID: 14737169
    [Abstract] [Full Text] [Related]

  • 11. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K.
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr 22; 32(2):92-101. PubMed ID: 19404007
    [Abstract] [Full Text] [Related]

  • 12. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J.
    Proc Natl Acad Sci U S A; 2011 Jan 11; 108(2):751-6. PubMed ID: 21177428
    [Abstract] [Full Text] [Related]

  • 13. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V.
    Br J Pharmacol; 2009 Nov 11; 158(5):1173-82. PubMed ID: 19814729
    [Abstract] [Full Text] [Related]

  • 14. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
    Hisano Y, Kobayashi N, Kawahara A, Yamaguchi A, Nishi T.
    J Biol Chem; 2011 Jan 21; 286(3):1758-66. PubMed ID: 21084291
    [Abstract] [Full Text] [Related]

  • 15. [Effects of sphingosine 1-phosphate on functions of T cell - review].
    Huang WR, Wang LS, DA WM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug 21; 13(4):718-22. PubMed ID: 16129068
    [Abstract] [Full Text] [Related]

  • 16. FTY720: mechanism of action and potential benefit in organ transplantation.
    Brinkmann V.
    Yonsei Med J; 2004 Dec 31; 45(6):991-7. PubMed ID: 15627289
    [Abstract] [Full Text] [Related]

  • 17. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
    Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y, Natarajan V, Garcia JG.
    Cell Signal; 2007 Aug 31; 19(8):1754-64. PubMed ID: 17475445
    [Abstract] [Full Text] [Related]

  • 18. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
    Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, Milstien S, Spiegel S.
    Blood; 2007 Feb 01; 109(3):1077-85. PubMed ID: 17008548
    [Abstract] [Full Text] [Related]

  • 19. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K.
    Yakugaku Zasshi; 2009 Jun 01; 129(6):655-65. PubMed ID: 19483408
    [Abstract] [Full Text] [Related]

  • 20. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
    Hiestand PC, Rausch M, Meier DP, Foster CA.
    Prog Drug Res; 2008 Jun 01; 66():361, 363-81. PubMed ID: 18416311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.